Limits...
Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression.

Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D, Rennie MJ, Greenhaff PL - J. Physiol. (Lond.) (2015)

Bottom Line: Statins are associated with muscle myalgia and myopathy, which probably reduce habitual physical activity.Statin myalgic subjects had reduced whole body (P = 0.05) and leg (P < 0.01) glucose disposal, greater abdominal adiposity (P < 0.05) and differential expression of 33 muscle mRNAs (5% false discovery rate (FDR)), six of which, linked to mitochondrial dysfunction and apoptosis, increased at 1% FDR.Statin myalgia was associated with impaired muscle function, increased abdominal adiposity, whole body and leg insulin resistance, and evidence of mitochondrial dysfunction and apoptosis.

View Article: PubMed Central - PubMed

Affiliation: MRC/Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Nottingham, NG7 2UH, UK.

No MeSH data available.


Related in: MedlinePlus

Body composition of control and statin user groupsValues are expressed as mean ± SEM. *P < 0.05 when comparing arm fat mass, and †P < 0.05 when comparing trunk fat mass between control and statin myalgic subjects.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4358682&req=5

fig02: Body composition of control and statin user groupsValues are expressed as mean ± SEM. *P < 0.05 when comparing arm fat mass, and †P < 0.05 when comparing trunk fat mass between control and statin myalgic subjects.

Mentions: There was no difference in regional (arm, trunk, leg) lean tissue mass (Fig. 2) when comparing control and statin myalgic subjects. However, arm and trunk fat mass was significantly greater in statin myalgic subjects (Fig. 2, P < 0.05).


Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression.

Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D, Rennie MJ, Greenhaff PL - J. Physiol. (Lond.) (2015)

Body composition of control and statin user groupsValues are expressed as mean ± SEM. *P < 0.05 when comparing arm fat mass, and †P < 0.05 when comparing trunk fat mass between control and statin myalgic subjects.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4358682&req=5

fig02: Body composition of control and statin user groupsValues are expressed as mean ± SEM. *P < 0.05 when comparing arm fat mass, and †P < 0.05 when comparing trunk fat mass between control and statin myalgic subjects.
Mentions: There was no difference in regional (arm, trunk, leg) lean tissue mass (Fig. 2) when comparing control and statin myalgic subjects. However, arm and trunk fat mass was significantly greater in statin myalgic subjects (Fig. 2, P < 0.05).

Bottom Line: Statins are associated with muscle myalgia and myopathy, which probably reduce habitual physical activity.Statin myalgic subjects had reduced whole body (P = 0.05) and leg (P < 0.01) glucose disposal, greater abdominal adiposity (P < 0.05) and differential expression of 33 muscle mRNAs (5% false discovery rate (FDR)), six of which, linked to mitochondrial dysfunction and apoptosis, increased at 1% FDR.Statin myalgia was associated with impaired muscle function, increased abdominal adiposity, whole body and leg insulin resistance, and evidence of mitochondrial dysfunction and apoptosis.

View Article: PubMed Central - PubMed

Affiliation: MRC/Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Nottingham, NG7 2UH, UK.

No MeSH data available.


Related in: MedlinePlus